Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Aims To Resolve OTC Labeling Issues At Three Upcoming Meetings

This article was originally published in The Tan Sheet

Executive Summary

FDA will meet with over-the-counter drug and cosmetics trade associations as many as three more times to discuss outstanding concerns regarding the OTC labeling final rule.

You may also be interested in...



P&G, Gillette First Sponsors Of MIT Auto-ID Research Center

Alternatives to UPC codes employed on retail products will be developed at a new Massachusetts Institute of Technology research center co-funded by Procter & Gamble and Gillette. The project was announced in conjunction with the recent 25th anniversary of the Universal Product Code.

P&G, Gillette First Sponsors Of MIT Auto-ID Research Center

Alternatives to UPC codes employed on retail products will be developed at a new Massachusetts Institute of Technology research center co-funded by Procter & Gamble and Gillette. The project was announced in conjunction with the recent 25th anniversary of the Universal Product Code.

OTC Labeling Exemption Requests For Ophthalmics Denied By FDA

Two requests for exemptions from certain provisions of the OTC labeling final rule are denied by FDA in Aug. 23 letters to the applicant companies.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090219

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel